Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
143 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Calvary Mater Newcastle
Waratah, New South Wales, Australia
- Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
- Austin Health-Austin Hospital
Heidelberg, Victoria, Australia
- Adelaide Cancer Centre
Kurralta Park, Australia
- Macquarie University Hospital
Macquarie Park, Australia
- Institut Jules Bordet
Brussels, Belgium
- Grand Hopital de Charleroi - Site Notre Dame - Oncology
Charleroi, Belgium
- Az Maria Middelares Gent
Ghent, Belgium
- Universitair Ziekenhuis Gent
Ghent, Belgium
- Hopital de Jolimont
Haine-Saint-Paul, Belgium
- Az Nikolaas
Sint-Niklaas, Belgium
- Gza Sint Augustinus
Wilrijk, Belgium
- Moncton Hospital - Horizon Health Network
Moncton, New Brunswick, Canada
- Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- Sunnybrook Health Science Centre
Toronto, Ontario, Canada
- Ciusss de L Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
- Chu de Quebec - Hotel-Dieu de Quebec
Québec, Quebec, Canada
- Institut de Cancerologie de L Ouest Site Paul Papin
Angers, France
- Chu de Besancon
Besançon, France
- Institut Bergonie
Bordeaux, France
- Centre Jean Perrin
Clermont-Ferrand, France
- Institut Paoli Calmettes
Marseille, France
- Centre D Oncologie de Gentilly
Nancy, France
- Hopital Europeen Georges Pompidou
Paris, France
- Centre Hospitalier Lyon Sud
Pierre-Bénite, France
- Institut Jean Godinot
Reims, France
- Chu de Strasbourg - Nouvel Hopital Civil
Strasbourg, France
- Institut Claudius Regaud
Toulouse, France
- C.H.U. de Tours - Hopital Bretonneau
Tours, France
- Institut Gustave Roussy
Villejuif, France
- Universitaetsklinikum Schleswig-Holstein. Campus Luebeck
Lübeck, Schleswig-Holstein, Germany
- Universitaetsklinikum Duesseldorf
Düsseldorf, Germany
- Kliniken Essen Mitte
Essen, Germany
- Universitatsklinikum Hamburg-Eppendorf
Hamburg, Germany
- Universitaetsklinikum Jena
Jena, Germany
- Universitaetsklinikum Magdeburg A.O.R.
Magdeburg, Germany
- Klinikum Rechts Der Isar Der Technischen Universitat
München, Germany
- Krankenhaus Der Barmherzigen Brueder Trier
Trier, Germany
- Universitaetsklinikum Tuebingen
Tübingen, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Dec 2017
- Primary completion
- 9 Aug 2018
- Completion
- 4 Aug 2020
- Last update posted
- 22 Aug 2025
- Registered enrollment
- 93
- Registry id
- NCT03361865
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.